4.70
+0.51(+12.17%)
Currency In USD
| Previous Close | 4.19 |
| Open | 4.44 |
| Day High | 4.93 |
| Day Low | 4.3 |
| 52-Week High | 4.93 |
| 52-Week Low | 1.3 |
| Volume | 228,110 |
| Average Volume | 45,558 |
| Market Cap | 82.9M |
| PE | -4.75 |
| EPS | -0.99 |
| Moving Average 50 Days | 3.01 |
| Moving Average 200 Days | 2.29 |
| Change | 0.51 |
If you invested $1000 in Exagen Inc. (XGN) since IPO date, it would be worth $274.69 as of December 04, 2024 at a share price of $4.7. Whereas If you bought $1000 worth of Exagen Inc. (XGN) shares 3 years ago, it would be worth $523.97 as of December 04, 2024 at a share price of $4.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
GlobeNewswire Inc.
Nov 14, 2024 9:30 PM GMT
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune diseaseCARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today an
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
GlobeNewswire Inc.
Nov 13, 2024 9:05 PM GMT
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity Me
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
GlobeNewswire Inc.
Oct 29, 2024 8:05 PM GMT
CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024, before the market opens on Tuesday, November 12, 2024.